Nutritional Advice El Mondo
Objectives:
Severe COVID-19 cases have a detrimental hyper-inflammatory host response and different cytokine-blocking biologic agents were explored to improve outcomes. Anakinra blocks the activity of both IL-1α and IL‑1β and is approved for different autoinflammatory disorders, but it is used off-label for conditions characterized by an excess of cytokine production. Several studies on anakinra in COVID-19 patients reported positive effects. Therefore, this review article has been conducted.
Does anakinra use reduce COVID-19 severity and mortality?
Study design:
This review article included 4 observational studies involving 184 COVID-19 patients (111 received anakinra and 73 received standard treatment).
No randomized clinical trials were identified and all studies were retrospective.
Overall risk of bias of included studies was high.
Results and conclusions:
The investigators found overall mortality of patients treated with anakinra was significantly lower than mortality in the control group [95% CI = 0.14 to 0.48, p 0.0001].
The investigators found, moreover, patients treated with anakinra had a significantly lower risk of need for mechanical ventilation than controls [95% CI = 0.25 to 0.74, p = 0.002].
The investigators found no difference in adverse events and discharge at home with no limitations was observed.
The investigators found the trial sequential analysis z-cumulative line reached the monitoring boundary for benefit and the required sample size.
The investigators concluded administration of anakinra in COVID-19 patients is safe and might be associated with reductions in both mortality and need for mechanical ventilation. Randomized clinical trials are warranted to confirm these findings.
Original title:
Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies by Pasin L, Cavalli G, […], Monti G.
Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862887/
Additional information of El Mondo:
Find more information/studies on corona virus right here.